Friends,This week in the Beyond the Basics/Treatment section of our website, we’ve posted an article about another treatment under investigation called IPI-145 or duvelisib, a PI3 kinase inhibitor. You can read about how it works, the data that has been released and ongoing clinical trials here. [http://cllsociety.org/2016/05/ipi-145-duvelisib-cll/]In other news, the FDA expanded the Imbruvica® (ibrutinib) label to include overall survival data in previously untreated CLL and added a new indication for small lymphocytic lymphoma (SLL) patients. Read more about it in our News section here. [http://cllsociety.org/2016/05/fda-expands-imbruvica-label-include-os-data-plus-new-indication-sll/]THANK YOU AGAIN TO OUR READER POLL PARTICIPANTS!Data analysis is in progress and we are really excited with the preliminary results. We really appreciate the time you spent to contribute to our research and look forward to sharing the data in the future.In the meantime….Stay strong.We are all in this together.
Brian Koffman, MDVolunteer Medical Director of the CLL Societyhttp://cllsociety.orgIf you want a personal response, or just want to stay in touch, please email me at bkoffmanMD@gmail.com. I have no other way of contacting. Thanks. Stay strong. After all, we are all in this together. And please visit our website: http://cllsociety.org for the latest news and information.